Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...

Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3, DLL3, MUC1, MET, and HER2 and master regulators of transcription, such as AR, ER, FOXA1, ASCL1, and ...

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease Precede ...

Rehan Verjee is no stranger to making medicines, having taken several candidates through FDA approvals as the former president of EMD Serono and global head of the Innovative Medicine Franchises at ...

A sleek and functional electric city commuter. Clean lines, aerodynamic design. Loads of accessories. Powerful pedal assistance up to 28 mph. Display can be hard to see in bright sun. You’ll feel the ...

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET test showed high concordance with tissue ...

Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers ...

International consortium reports high rates of baseline imaging completion in patients considered at risk for pancreatic cancer. Such a surveillance program may lead to improved outcomes. PLYMOUTH ...

SAN DIEGO--(BUSINESS WIRE)--ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced ...

The Canyon Precede:ON CF 9 is this week’s Bike of the Week and, with its impressive levels of integration and wildly angular Tron-like aesthetic, you could also feasibly call this a vision of the Bike ...